Secukinumab

司库奇尤单抗

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NameSecukinumab
Drug Alias NameSecukinumabum瑟库吉努单抗Kosentikusu苏金单抗Cosentyx +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisPalmoplantar pustulosis +[43] 
Global Approved IndicationsPlaque psoriasisPsoriasisArthritis, Psoriatic
Approved Indications in ChinaPlaque psoriasis
Original Approved Country/TerritoryJapan
Original Approved Date2014/12/26
Country/TerritoryCzechiaBelgiumBulgaria +[63] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesDuke UniversityNovartis Pharma Schweiz AgTaizhou Mabtech Pharmaceutical Co Ltd +[8] 
Inactive CompaniesUniversity Of LiverpoolGwt-Tud GmbhWake Forest University Health Sciences +[8] 
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisAxial Spondyloarthritis +[16] 
Inactive IndicationsPalmoplantar pustulosisTendon InjuriesInflammation +[27] 

Other Information

ATC CodeL04AC10
Related LinksWikipediaDrugBankKEGG